MedPath

Azilect

These highlights do not include all the information needed to use AZILECT® safely and effectively. See full prescribing information for AZILECT®. AZILECT® (rasagiline mesylate) Tablets for Oral Use Initial U.S. Approval: 2006

Approved
Approval ID

eb558270-1b12-4704-9b09-39f668f30529

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 7, 2010

Manufacturers
FDA

Physicians Total Care, Inc.

DUNS: 194123980

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

rasagiline mesylate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code54868-6206
Application NumberNDA021641
Product Classification
M
Marketing Category
C73594
G
Generic Name
rasagiline mesylate
Product Specifications
Route of AdministrationORAL
Effective DateDecember 7, 2010
FDA Product Classification

INGREDIENTS (5)

RASAGILINE MESYLATEActive
Quantity: 1 mg in 1 1
Code: LH8C2JI290
Classification: ACTIB
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
STEARIC ACIDInactive
Code: 4ELV7Z65AP
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Azilect - FDA Drug Approval Details